Document:

Joint Development Agreement

 Exhibit 10.41 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 Effective Date: November 1, 2011

 Joint Development Agreement 

between 
 BioAmber International
S.à.r.l. 
 1, rue Nicolas Simmer 

L-2538 Luxembourg 
 - hereinafter referred to as
BIOAMBER - 
 and 
 Lanxess
Deutschland GmbH, 
 [***] 
 -
hereinafter referred to as LXS - 
 both, BIOAMBER and LXS are hereinafter commonly referred to as PARTIES- 

WHEREAS, BIOAMBER has developed technology for manufacturing of bio-based succinic acid; 
 WHEREAS, LXS has experience in developing, manufacturing and marketing of phthalate-free speciality plasticizers; 
 WHEREAS, the PARTIES, in case of BIOAMBER through BIOAMBER’s AFFILIATE BIOAMBER S.A.S. with registered seat in France, have executed a Memorandum Of Understanding (MOU) dated July 4, 2011,
documenting their intent in working together for a period of time; for sake of clarity, as provided under section 3.1 of the MOU, the MOU will be terminated as of the EFFECTIVE DATE of this Agreement; 

WHEREAS, on the basis of the MOU, the PARTIES have decided to cooperate, on an exclusive basis as set forth herein, in the field of research and
development of plasticizers based on bio-based succinic acid in order to conduct and complete a Feasibility Study; 
 NOW, THEREFORE, the
PARTIES agree as follows: 
  

	1.	Definitions 

  

	1.1	AFFILIATE shall mean, with respect to each PARTY, any corporation or other business entity directly or indirectly controlling, controlled by or under common control
with such PARTY, or any entity in which such PARTY holds a fifty percent (50%) or more equity or voting interest. As used herein, the term CONTROL means possession of the power to direct, or cause the direction of the management and policies of
a corporation or other entity, whether through the ownership of voting securities, by contract or otherwise. 

  
 * Confidential
treatment requested 

	1.2	COMMITTEE shall mean a steering committee of an equal number of members appointed by LXS and BIOAMBER. 

 

	1.3	EFFECTIVE DATE shall mean the date on which the present Agreement shall enter into force. 

 

	1.4	FEASIBILITY STUDY shall mean research and development work as agreed to between the PARTIES relating to plasticizers based on bio-based succinic acid.

  

	1.5	INFORMATION shall mean any and all confidential information owned by either BIOAMBER or LXS and exchanged in writing, orally, visually or by electronic means between
the PARTIES in connection with the FEASIBILITY STUDY. 

  

	1.6	PRODUCTS shall mean [***] plasticizers based on bio-based succinic acid. 

  

	1.7	RESULTS shall mean any and all results, including inventions, achieved by the PARTIES in connection with the FEASIBILITY STUDY. 

 

	1.8	SCOPE shall mean the projects within the FEASIBILITY STUDY. 

  

	1.9	THIRD PARTIES shall mean natural or legal entities other than LXS and BIOAMBER and their AFFILIATES. 

 

	2.	Subject of the cooperation 

  

	2.1	During the term of this Agreement, the PARTIES agree to work together in order to conduct the FEASIBILITY STUDY. 

 

	2.2	The PARTIES, in the case of BIOAMBER through BIOAMBER’s AFFILIATE BIOAMBER INC., a Delaware corporation having a corporate office located at 1250 Rene-Levesque
West, Suite 4110, Montreal, Quebec, Canada, and in the case of LXS LANXESS CORPORATION, a Delaware corporation having its headquarters at 111 RIDC Park West Drive, Pittsburgh, Pennsylvania, are negotiating a Stock Purchase Agreement including
Exhibit B “Heads of Agreement”. In case that any conflicts should occur between the regulations of this Agreement and the Stock Purchase Agreement, the regulations of the Stock Purchase Agreement shall prevail. 

 

	2.3	The FEASIBILITY STUDY shall have the following 

 SCOPE: 
  

	 	•	 	 developing of PRODUCTS, 

  

	 	•	 	 developing of knowledge about the applicability of the PRODUCTS as plasticizers, 

 

	 	•	 	 developing of knowledge about the suitability of the PRODUCTS in the relevant customers’ end-use applications 

 

	 	•	 	 determination of market opportunities for the PRODUCTS. 

 The SCOPE may be subject of amendments and/or additions if mutually agreed by the PARTIES in writing. 
  

	2.4	 During the term of this Agreement and within the SCOPE of the FEASIBILITY STUDY, the PARTIES will not work with anyone else other than by mutual
agreement, i.e. their cooperation shall be exclusive. Notwithstanding the preceding, the exclusivity granted herein by BIOAMBER shall not apply to the Joint Development Agreement between Solvay SA and BIOAMBER entered into effect on
October 1st, 2011, which is related to the
development of products to be used in the field of the plasticization of polyvinyl chloride (PVC). 

  
 - 2 -

 * Confidential treatment requested 

	2.5	BIOAMBER shall provide LXS with sufficient amounts of bio-based succinic acid to [***]. BIOAMBER shall provide [***]. 

 

	2.6	LXS shall provide [***] in order to manufacture PRODUCTS. If PRODUCTS pass LXS’ in-house standard tests, LXS shall supply customers with samples of PRODUCTS for
evaluating their efficiency in customer’s plasticizer applications. 

  

	2.7	LXS and BIOAMBER shall evaluate feedback from the customers. In case of positive results LXS and BIOAMBER shall determine the commercial potential of PRODUCTS and
evaluate market opportunities. 

  

	2.8	A time schedule outlining milestones of the FEASIBILITY STUDY is attached in Annex 1, it being understood that the schedule and milestones are subject to change and
will be updated from time to time by the PARTIES. 

  

	3.	COMMITTEE 

  

	3.1	The PARTIES agree to establish a COMMITTEE for the organization and supervision of the cooperation within the SCOPE. 

 

	3.2	The COMMITTEE shall be responsible for major decisions concerning the cooperation such as: 

 

	 	•	 	 supervising the performance of projects within the SCOPE; 

 

	 	•	 	 deciding when the development of any specific project within the SCOPE is completed; 

 

	 	•	 	 evaluating completed projects within the SCOPE; 

  

	 	•	 	 deciding about the publication of any RESULTS obtained during the FEASIBILITY STUDY. 

 

	3.3	The initial members of the COMMITTEE are listed in Annex 2, attached hereto and made part hereof. If LXS and/or BIOAMBER intend to replace any member of the COMMITTEE,
the PARTY concerned shall notify the other PARTY in writing of such intention prior to making any such replacement. 

  

	3.4	The COMMITTEE shall meet at least [***] and at any other time determined by the COMMITTEE. 

 

	3.5	Only the members of the COMMITTEE appointed pursuant to Article 3.1 hereof or their proxies shall be entitled to decide any matters presented to the COMMITTEE. Any
other participants at the meeting of the COMMITTEE, shall only have an advisory function and shall not be entitled to vote on any matters to be decided by the COMMITTEE. 

 

	3.6	All decisions of the COMMITTEE shall be made either (i) in person by the members of the COMMITTEE or their proxies at the meetings of the COMMITTEE pursuant to
Article 3.4, or (ii) in writing signed by all members of the COMMITTEE. All decisions of the COMMITTEE shall be unanimous. 

  
 - 3 -

 * Confidential treatment requested 

	4.	Costs 

  

	4.1	The PARTIES will [***] all external and out of pocket costs arising from the conduction of the FEASIBILITY STUDY, subject to prior approval by both PARTIES, it being
understood that (i) BIOAMBER shall provide LXS with [***] for the purposes of the FEASIBILITY STUDY, [***], and (ii) the labor costs of the personnel of each PARTY involved in the FEASIBILITY STUDY shall be assumed by each Party [***]
between the PARTIES. 

  

	5.	Time limits 

  

	5.1	For the joint research and development according to Article 2.1 the PARTIES agree to a period commencing on the EFFECTIVE DATE and ending [***] unless extended by prior
written agreement of the PARTIES, it being understood that this Agreement shall govern the rights and obligations of the Parties with respect to any part of the FEASIBILITY STUDY that could have been undertaken prior to the EFFECTIVE DATE of this
Agreement. 

  

	6.	Rights in the RESULTS 

  

	6.1	The RESULTS achieved by the PARTIES in connection with the FEASIBILITY STUDY shall be [***]. 

 

	6.2	For the avoidance of any doubt, this Agreement bestows no rights on the PARTIES other than defined in this Agreement. Each PARTY shall retain the control and ownership
(i) of its proprietary rights that existed prior to this Agreement and (ii) of any rights developed independently during the FEASIBILITY STUDY provided such rights developed independently are not related to the FEASIBILITY STUDY.

  

	7.	Patent rights for the RESULTS 

  

	7.1	[***]. The external costs (fees and professional charges) of a [***] between the PARTIES, regardless of any inventors’ shares of [***] properties.

  

	7.2	If either of the PARTIES does not wish to make use of its right to file patent applications [***], the other PARTY will have the right to do so if, within a period of 1
(one) month after the receipt of a corresponding notification, the PARTY announces in writing that it intends to file the patent application at its own expense. Such patent right will become the sole property of the filing PARTY. The other PARTY
shall provide the filing PARTY with all required declarations and assignments including those of the inventors involved. 

  

	7.3	Article 7.2 applies accordingly where a patent application [***] or a patent granted thereon shall be abandoned. 

 

	7.4	Where inventions [***] are made, both PARTIES will consult and inform each other with regard to the drafting of the patent applications and the handling of the
examination procedure and the patents. The PARTIES will decide on a case-by-case basis which of the PARTIES will be responsible for prosecuting/handling the patent applications and patents before the various patent offices or, where necessary,
courts or other authorities. If, in order to meet specific deadlines, rapid decisions have to be made in relation to existing patent applications or patents the PARTY prosecuting/handling the patent applications or patents will have the right to
make all such decisions (including decisions to file priority applications) in order to ensure that the patents/patent applications concerned are maintained with the largest possible scope. Notwithstanding the above, the PARTY handling the
patent/patent application shall notify the other PARTY three days prior to making a decision. 

  
 - 4 -

 * Confidential treatment requested 

	7.5	If one PARTY wishes to completely or partially abandon patent rights for RESULTS It will inform the other PARTY accordingly in writing. The other PARTY will then decide
as quickly as possible whether it agrees with the proposal, while taking into consideration any existing deadlines (such as for example for payments) but not later than 2 (two)calendar months after the receipt of the information. If the requesting
PARTY does not get a decision within two (2) calendar months after the request, the requesting PARTY may withdraw the patent right concerned. If patent rights are not abandoned at the mutual consent of the PARTIES, that PARTY which is not in
agreement with the abandonment decision will have the right to continue the prosecution of the corresponding patent right by itself, in its own name and at its own expense. Such patent rights will become the property of the continuing PARTY and are
to this extent no longer considered patent rights for RESULTS under this Agreement. In this case the other Party shall provide the filing party with all required declarations and assignments, including those of the inventors i involved.

  

	7.6	The PARTIES shall immediately inform each other of any infringement by THIRD PARTIES of any patent rights arising from patent applications pursuant to [***] and shall
discuss appropriate steps to be taken against the infringer. In the event that the PARTIES agree to take legal action against the infringer of any such proprietary rights, the external costs arising from such action and the awards of any such
litigation [***]. Either PARTY may elect to fund and shall be entitled to any such awards if the other PARTY does not agree to participate in the prosecution or settlement of any such infringement. 

 

	7.7	Any arrangement between BIOAMBER or LXS and THIRD PARTIES concerning amicable settlement of any infringements dispute under Article 7.6 hereof shall require the prior
written agreement of the other PARTY. 

  

	8.	Exploitation of the RESULTS 

  

	8.1	Each PARTY (including its AFFILIATES) shall have the right to make unrestricted use of the RESULTS according to Article 6.1 only for its internal use.

  

	8.2	BIOAMBER and LXS shall have the right to [***]. 

  

	8.3	BIOAMBER and LXS shall have the right to make [***]. 

  

	9.	Subsequent Agreements 

  

	9.1	Any arrangements relating to regulatory approval (Reach, food contact or others) for PRODUCTS shall be made subject to a separate agreement between the PARTIES.

  

	9.2	The PARTIES will negotiate in good faith a joint venture agreement within six (6) months of successfully finalizing the FEASIBILITY STUDY. [***]

  

	10.	Confidentiality 

  

	10.1	 The PARTIES have entered into a Secrecy Agreement dated February 3, 2009, extended by Amendment of February 3, 2011 until February 3,
2013. The disclosing period of the Secrecy Agreement shall be extended for the term of this Agreement 

  
 - 5 -

 * Confidential treatment requested 

	 	
including any extension thereof. Further, the obligations of confidentiality shall extend beyond the termination of this Agreement for a period of [***] years. Any confidential information
disclosed by one PARTY to the other PARTY under this Agreement including RESULTS shall be deemed to be INFORMATION as defined in the existing Secrecy Agreement. 

 

	10.2	Any disclosure of RESULTS, including the filing of any patent application for RESULTS must be agreed by the PARTIES. 

 

	11.	Patent Rights of THIRD PARTIES 

  

	11.1	Prior to deciding that a PRODUCT is ready for industrial use the PARTIES will ensure that an examination is carried out to determine whether the patent rights of a
third party could interfere with the PRODUCT(S) and/or their use. 

  

	11.2	The PARTIES will immediately notify each other if any third party asserts any patent right against LXS, BIOAMBER or any AFFILIATE of one of the PARTIES in connection
with the PRODUCT(S) or their use. 

  

	12.	Responsibilities 

  

	12.1	The responsibility of each PARTY in connection with this Agreement shall be limited to all actions it has performed. Therefore the PARTIES will mutually hold harmless
themselves for any claims of THIRD PARTIES. 

  

	13.	Termination 

  

	13.1	Subject to Article 13.2 the Agreement shall come into force on the EFFECTIVE DATE and shall regularly expire upon the expiration of the joint development period
according to Article 5. 

  

	13.2	The provisions according to Article 6, 7, 8, and 10 shall survive any expiration of this Agreement until the expiration of the last proprietary right according to
Article 7.1 or the expiration of confidentiality undertaking according to Article 10. 

  

	13.3	This Agreement may be terminated at any time upon the failure of either LXS or BIOAMBER to fulfill its contractual obligations. The PARTY aggrieved by such default may
give the other PARTY notice of its complaints (the notice shall specifically indicate the PARTY’s intention to terminate the Agreement), and, if within 60 (sixty) days of such notice, the defaulting party has failed or refused to remedy such
default, the aggrieved PARTY may terminate this Agreement with immediate effect upon notice to the defaulting PARTY. Such termination shall be without prejudice to other rights or claims the aggrieved PARTY may have against the defaulting PARTY. Any
payment obligations and any obligation to confidentiality will not be affected by the termination of the Agreement. The right to terminate the Agreement without notice for pertinent reasons is unaffected by this provision. 

 

	13.4	Either PARTY may terminate this Agreement by giving immediate notice to the other PARTY in the event that the other PARTY is bankrupt, insolvent, undergoes liquidation,
or if the business of the other PARTY is placed in the hands of a receiver, assignee or trustee, or 

  

	13.5	Either PARTY may terminate this Agreement by giving immediate notice to the other PARTY in the event that a competitor engaged in the business of the other PARTY
acquires a significant share or influence in the board of directors, the supervisory board or the general assembly of the other PARTY. 

  

	13.6	In case of a termination according to Article 13.3 or 13.4, the defaulting PARTY forfeits its right in the RESULTS on the effectiveness of the termination.

  
 - 6 -

 * Confidential treatment requested 

	14.	General Provisions 

  

	14.1	The PARTIES bear no liability towards each other for any non-fulfillment of the obligations of this Agreement due to an event of force majeure. The PARTY affected by
the force majeure will immediately notify the other PARTY of the existence and probable duration of the effects of the force majeure and will make every reasonable effort to keep the effects of the force majeure to a minimum. In the event that the
force majeure lasts more than 6 (six) months, the PARTIES shall meet to find a solution to the problem. 

  

	14.2	If any provision of this Agreement is declared or becomes invalid, the validity of the Agreement as a whole will not be affected. Where necessary, the PARTIES will
replace the invalid provisions by a valid one, the effect of which resembles as closely as possible that of the invalid clause. 

  

	14.3	Any amendment or modification of this Agreement must be made in writing and signed by the PARTIES. 

 

	14.4	No rights or obligations of the PARTIES under this Agreement shall be assigned, of in whole or in part to any THIRD PARTY, without the written consent of each PARTY
concerned. 

  

	14.5	This Agreement shall inure to the benefit of, and be binding upon, the PARTIES and their successors in interest. This Agreement shall be interpreted, construed and
enforced in accordance with the laws of the Federal Republic of Germany, without regard to its conflicts-of-law principles. In the event any dispute, controversy, or difference of opinion arises between the PARTIES hereunder out of or in relation to
or in connection with this Agreement or the breach thereof, the PARTIES hereto shall first endeavor to come to an amicable settlement. If an amicable settlement between the parties is not possible, the legal venue will be Cologne.

  

	14.6	All communications under the present Agreement shall be transmitted to the other PARTY concerned in each case in writing by registered mail, telex or facsimile to the
address mentioned below. 

 All communications to LXS concerning technical questions shall be addressed to:

 Lanxess Deutschland GmbH 
 [***] 
 All communications to LXS concerning general and legal questions shall be
addressed to: 
 Lanxess Deutschland GmbH 
 [***] 

  
 - 7 -

 * Confidential treatment requested 

 All communications to BIOAMBER concerning technical, general and legal aspects shall be
addressed to 
 [***] 
 BioAmber S.A.S 
 Route de Bazancourt 

51110 Pomacle, 

France 
 [***]

 For LANXESS Deutschland GmbH 
  

			
	Place: Leverkusen, Germany	 	 /s/ [***]

		
		 	[***]
		
	Date: January 25, 2012	 	 /s/ [***]

		
		 	[***]

 For BioAmber International S.à.r.l. 
 Place: 1, rue Nicolas Simmer L-2538 Luxembourg 
  

			
		 	 /s/ Jean-François Huc

		
		 	Jean-François Huc, Manager
		
		 	 /s/ [***]

		
		 	[***]
		
	Date:	 	

  
 - 8 -

 * Confidential treatment requested 

 Annex 1 
 Milestones 
 [***] 

  
 * Confidential
treatment requested 

 Annex 2 
 Members of the COMMITTEE 
 [***] 

  
 - 10 -

 * Confidential treatment requestedJoint Development Agreement

 Exhibit 10.42 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested

 Under 17 C.F.R. §§ 200.80(b)(4) 
 and 203.406 
 JOINT DEVELOPMENT AGREEMENT 

 

					
	Parties:	 	SOLVAY SA, a company incorporated in Belgium with its registered office located at [***],	  	Bioamber International S.à.r.l., a company incorporated in Luxembourg with its registered office located at [***],
			
		 	hereinafter referred to as “Solvay”	  	hereinafter referred to collectively as “Bioamber”
		
	Recitals:	 	 Solvay, as an international chemical company, is active in research and development of various technologies, products and
applications such as, but not limited to, the plasticization of polymers, and owns proprietary and valuable information related to the same.
  

Bioamber is engaged in the development, production and sales of bio-based succinic acid and salts of succinic acid, and derivatives thereof and
technologies for producing them.
  
 Solvay and Bioamber wish to collaborate
to fulfill the Purpose (as hereinafter defined).

			
	Definitions:	 		  	
		
	 “Purpose”
	 	means the development of Product according to the Program for use in the Application.
		
	 “Product”
	 	means aliphatic and/or aromatic esters of (i) bio-succinic acid, and/or (ii) its derivatives.
		
	 “Application”
	 	means the plasticization of polyvinyl chloride (PVC).
		
	 “Effective Date”
	 	means [***].
		
	 “JDA Term”
	 	means [***] from the Effective Date.
		
	 “NDA”
	 	means the Non-Disclosure Agreement entered on 1 February, 2011 between Solvay and Bioamber S.A.S., an Affiliate of Bioamber Inc.
		
	 “Secrecy Period”
	 	means the period starting on the Effective Date and ending [***] after the expiration, or termination for whatever cause, of this Joint Development
Agreement.
		
	 “Governing Law”
	 	means the law of France, excluding its conflicts of law principles.
		
	 “Arbitration Rules”
	 	means the Rules of Conciliation and Arbitration of the International Chamber of Commerce.
		
	“Arbitration Place”	 	means Paris (France).

 Operative provisions: 
 The parties agree to collaborate under the terms and conditions set forth hereabove and in the hereunder General Terms and Conditions. 

 

			
	    June 2011	 	Initials of parties:             

 * Confidential treatment requested 

 General Terms and Conditions 

1. ADDITIONAL DEFINITIONS 

 

	 	1.1.	In addition to the definitions given hereabove, the following capitalized terms shall have the following meanings: 

 

	 	(a)	“Affiliate” means, with respect to a party, any entity or person controlling, or controlled by, or under common control with, such party, whether
directly or indirectly; “control” (including, with correlative meanings, “controlling”, “controlled by”, and “under common control with”) meaning the power to cause the direction of the management of such
person or entity, directly or indirectly, whether through ownership of voting securities or otherwise. 

  

	 	(b)	“Background” shall mean either Background Solvay or Background Bioamber. 

 

	 	(c)	“Background Solvay” means any know-how and patent right related to the Purpose and [***], developed or acquired by Solvay independently of the receipt
of [***] from Bioamber and/or Agro-Industries Recherches et Développement (the former Bioamber joint venture partner in biobased succinic acid) both prior to and after the Effective Date, and which Solvay is free to disclose and license
without accounting to third parties, excluding the Results. 

  

	 	(d)	Background Bioamber” means any know-how and patent right related to the Purpose, the production of bio-succinic acid and/or its derivates, and the chemistry
based on such bio-succinic acid and/or derivatives, developed or acquired by Bioamber both prior to and after the Effective Date, and which Bioamber is free to disclose and license without accounting to third parties, excluding the Results.

  

	 	(e)	“Confidential Information” means (i) the existence and Purpose of this Agreement, (ii) any Background Solvay disclosed directly or indirectly
by Solvay to Bioamber under the NDA, or under this Agreement, including any material sample, (iii) any Background Bioamber disclosed directly or indirectly by Bioamber to Solvay under the NDA, or under this Agreement, including any material
sample, and (iv) any Results. 

  

	 	(f)	“Program” means the program set up by the parties for the fulfillment of the Purpose, including the tasks to be performed by each party and their
associated timing, as detailed in Appendix A hereto, and as may be amended pursuant to Sub-Clause 3.4. 

  

	 	(g)	“Result” means any data or information obtained, or any improvement or invention made, by either party, or jointly by both parties, through the
performance of the Program, but excluding any Background. 

  

	 	1.2.	The singular includes the plural and vice versa. 

 2. PURPOSE OF THE AGREEMENT 
  

	 	2.1.	The purpose of this Agreement is to define the terms which shall control the respective activities, rights and obligations of the parties with respect to the
performance of the Program, and the ownership and exploitation of the Results. 

 3. PERFORMANCE
OF THE PROGRAM 
  

	 	3.1.	Each party shall perform its tasks in accordance with the Program with the aim of having it completed within [***] from the Effective Date. 

 

	 	3.2.	Each party shall disclose to the other party its Background as it deems necessary for the performance of the Program. 

  
 2 

* Confidential treatment requested 

	 	3.3.	Each party shall disclose to the other party the Results it obtains at regular intervals. 

 

	 	3.4.	The parties shall be entitled to jointly amend the Program, including the associated timing, as they deem appropriate. 

 

	 	3.5.	Each party shall support all costs and expenses it may incur during the performance of the Program. 

 

	 	3.6.	Solvay shall be entitled to have any of its activities hereunder performed by any of its Affiliates, including, but not limited to, by [***]. 

 

	 	3.7.	The parties shall explore jointly in good faith the possibility to appeal to sub-contractors that could bring [***]. 

4. INTELLECTUAL PROPERTY 
 Background Technology 
  

	 	4.1.	Each party shall retain full ownership of its Background. 

  

	 	4.2.	Each party shall be entitled to use the other party’s Background as disclosed pursuant to section 3.2 for the purpose of performing its tasks under the Program.

 Ownership and protection of the Results 

 

	 	4.3.	(a) The parties shall [***] all Results and shall examine the best means to protect them. In case they elect to patent any Result, the parties shall determine the party
(the “Filing Party”) that will (i) file, in its own name, the patent application(s) embodying such Result in the relevant countries jointly agreed upon by the parties, and (ii) take all actions in connection with the
prosecution, maintenance and defense of such patent application(s), and of all patents derived therefrom. The parties shall [***] all external expense incurred for such purposes by the Filing Party. 

(b) Each party shall be entitled to file patent applications embodying Result in its name and at its expense in those countries where the
other party does not wish to file. 
 (c) Each party shall be entitled to continue, in its name and at its expense, the
prosecution, maintenance or defense of any patent right resulting from the actions taken under Sub-Clause 4.3(a) in the event the other party does not wish to continue the same. 

 

	 	4.4.	The other party shall provide assistance, do any act and execute any document, as may be requested by the Filing Party for the purpose of protecting any Results
pursuant to Sub-Clause 4.3. 

  

	 	4.5.	Each party shall be responsible for remunerating its employed inventors according to applicable inventors’ laws. 

Exploitation rights of the Results 
  

	 	4.6.	Upon successful completion of the Program and provided the Results are deemed satisfactory by both parties, the parties shall jointly decide the way to exploit [***]
such Results [***]. 

  

	 	4.7.	In case, (i) the Results are [***], or (ii) despite their reasonable endeavors, the parties [***]; 

 

	 	(a)	The parties shall [***]. 

  

	 	(b)	Upon each party’s request, the other party shall [***]. 

  

	 	(c)	Upon either party’s request, the other party shall negotiate in good faith [***]. 

5. REPRESENTATION, WARRANTIES AND RESPONSIBILITIES 

 

	 	5.1.	Representation. Each party represents and warrants that it has the right to enter into this Agreement and to fulfill its obligations hereunder, and that it is
under no contract or agreement, and will not enter into any contract or agreement during or after the term of this Agreement that will prevent it from performing its duties and obligations under this Agreement. 

  
 3 

* Confidential treatment requested 

	 	5.2.	Disclaimer of warranties. Neither party makes any warranties, express, implied, statutory or otherwise, concerning any information, results or materials provided
to the other party under this Agreement. In particular, any and all warranties, including, but not limited to, any warranty of merchantability, non-infringement of third party intellectual property rights, fitness for a particular purpose, and any
other warranty arising from the course of performance; course of dealing or usage in the trade of the same, are hereby disclaimed. 

  

	 	5.3.	Limitation of liability. Except in case of gross negligence, willful misconduct, or fraudulent misrepresentation, neither party nor its employees shall be liable
to the other party for any loss, damage, costs or expenses of any nature whatsoever incurred or suffered of an indirect, incidental or consequential nature, including any economic loss or other loss of turnover, loss of profits, business or goodwill
arising out of the performance of the Program, the use of any Background or Result, and/or the handling, use or disposal of any material sample, apparatus, equipment, method or process. 

 

	 	5.4.	Indemnification for bodily injury. Each party shall indemnify the other party, its Affiliates and subcontractors for any damages any representative of any of the
foregoing may suffer as result of personal bodily injury, including death, or property damage or loss which may occur while such representative is performing any activity under this Agreement in the premises of the indemnifying party and which is
due to the negligence or willful misconduct of the indemnifying party, or its Affiliates, or employees or subcontractors of any of the foregoing. 

 6. CONFIDENTIALITY AND PUBLICATION 
  

	 	6.1.	Obligations. With respect to Confidential Information, the receiving party shall: 

(a) use the same degree of care as it uses for protecting its own confidential information of a like nature (but in no event less than a
reasonable degree of care), including, by keeping the same in tangible or documented form, in secure storage and reasonably separate from other information, 
 (b) not disclose the same to any third party except to its Affiliates, or as authorized under this Agreement, 
 (c) not use the same for any purpose other than as explicitly permitted under this Agreement, 
 (d) limit access to the same, on a strict need to know basis, to its and its Affiliates’ employees, requiring that access to perform the Program and/or exploit the receiving party’s rights
hereunder, provided such employees are subject to confidentiality obligations through appropriate agreements, have been informed by the receiving party of the obligations hereunder, and the receiving party remains responsible for any violation of
the obligations hereunder by such employees; 
 (e) not disassemble, analyze, or have others analyze, Confidential Information
(except Results) in the form of material samples to determine the chemical composition, microscopic structure or method of manufacture of such samples, except to the extent strictly required to fulfill the Purpose, and 

(f) upon request and option of the disclosing party, either return Confidential Information (except Results), including copies, extracts
and notes of the same, and material samples, to the disclosing party, or destroy (or delete permanently in the case of digital or electronic media) the same, except that the receiving party may retain one (1) copy of such Confidential
Information in limited access files in accordance with the terms of this Agreement for the sole purpose of determining its legal obligations hereunder with respect to such Confidential Information, and that this obligation shall not apply to
routinely created backup copies of electronic data. 
  

	 	6.2.	Exceptions. The obligations of Sub-Clause 6.1 shall not apply to any portion of Confidential Information that the receiving party can prove:

 (a) was available to the public prior to receipt or achievement hereunder, or becomes available to the public
thereafter through no fault or negligence of the receiving party, or 

  
 4 

* Confidential treatment requested 

 (b) was already in the receiving party’s possession and was obtained from a source
other than the disclosing party or any of its Affiliate prior to receipt or achievement hereunder, or 
 (c) was lawfully
obtained from a third party legally entitled to do so after the time of receipt or achievement hereunder, and the receiving party is free to disclose without breach of any of its obligations, or 

(d) was independently developed by or for the receiving party without using Confidential Information. 

For the purpose of this Article, any information which is specific, shall not be deemed to be within any of the foregoing exceptions,
merely because it is embraced by more general information which falls within any one or more of the foregoing exceptions. In addition, any combination of features shall not be deemed to be within any of the foregoing exceptions, merely because
individual features fall within any one or more of the foregoing exceptions, but only if the combination itself falls within any one of the foregoing exceptions. 
  

	 	6.3.	Disclosure upon process. In the event the receiving party is required to disclose Confidential Information under applicable law, regulation, supervisory
authority or other applicable judicial or governmental order, the receiving party shall (i) inform the disclosing party in writing before any disclosure thereof so that the disclosing party may seek an appropriate protective order,
(ii) give upon the disclosing party’s request all necessary information and support to ward off the disclosure thereof, (iii) ask the receiving third party to maintain confidentiality, and (iv) strictly limit the content of such
disclosure to that portion of Confidential Information that it is strictly compelled to disclose. In any event, the receiving party shall not oppose action by the disclosing party to obtain an appropriate protective order or other reliable assurance
that confidential treatment will be accorded to Confidential Information. 

  

	 	6.4.	Disclosure to consultants and sub-contractors. The receiving party shall be entitled to disclose Confidential Information to its consultants and sub-contractors,
provided (i) such disclosure is required for the performance of the Program and/or the exploitation of the receiving party’s rights hereunder, (ii) such consultants and sub-contractors have been informed by the receiving party of the
obligations hereunder, and (iii) the receiving party remains responsible for any violation of the obligations hereunder by such consultants and sub-contractors. 

 

	 	6.5.	Publication. Either party shall not make any use of the name of the other party, or of any of its Affiliates, in connection with this Agreement in any technical,
advertising, promotional or sales literature without the prior written consent of the other party, with the exception of publications required for, or resulting from, the filing of patent applications as provided hereunder. 

7. TERM AND TERMINATION 

 

	 	7.1.	Term. This Agreement shall enter into force as of the Effective Date, and unless terminated pursuant to Sub-Clause 7.2 or 7.3, shall remain in full force and
effect until the completion of the Program, or the JDA Term, whichever occurs first. 

  

	 	7.2.	Termination for breach or bankruptcy. Each party shall have the right, but shall be under no obligation, to terminate this Agreement if the other party:

 (a) is shown to be in breach or default in the performance of any of its obligations or covenants hereunder and
fails to remedy the same within sixty (60) days of a written notice to do so; 
 (b) ceases to do business; or 

  
 5 

* Confidential treatment requested 

 (c) is adjudged a bankrupt or has its assets placed in the hands of a receiver or make any
assignment or other accommodation for the benefit of creditors or files or has filed against it a petition for reorganization. 
  

	 	7.3.	Termination for convenience. Each party shall have the right to terminate this Agreement at any time if the Results so-far obtained are not satisfactory.

  

	 	7.4.	Survival. The provisions of Clauses 4 and 5, and of Sub-Clauses 6.5, 8.1 and 8.2, shall survive the expiration, or termination for any cause, of this Agreement.
The provisions of Sub-Clauses 6.1 to 6.4 shall survive the expiration, or termination for any cause, of this Agreement during the Secrecy Period. 

 8. MISCELLANEOUS 
  

	 	8.1.	Applicable Law. This Agreement shall be governed by and construed in accordance with the Governing Law. 

 

	 	8.2.	Arbitration. All disputes arising out of, or in connection with, the interpretation, performance and/or termination of this Agreement, which cannot be amicably
settled between the parties, shall be finally settled under the Arbitration Rules by one or more arbitrators appointed in accordance with such Arbitration Rules. Arbitration proceedings shall take place in the Arbitration Place, and shall be
conducted in the English language. The award rendered therein shall be final and binding upon the parties. The foregoing is without prejudice to each party’s right to seek injunctions and other relief in any appropriate court, to the extent
such relief is not available in arbitration. 

  

	 	8.3.	Clauses and Headings. Unless the context otherwise indicates, references to Clauses, Sub-Clauses and Appendices are to Clauses and Sub-Clauses of, and Appendices
to, this Agreement. Headings to Clauses and Sub-Clauses in this Agreement are included for the purpose of ease of reference only and shall not have any effect on the construction or the interpretation of this Agreement. 

 

	 	8.4.	Entire Agreement. This Agreement, as may be amended pursuant to the provisions hereof, constitutes the entire understanding between the parties in connection
with the Purpose, and supersedes any agreements, communications, understandings, promises, or any other arrangement, whether written or oral, made or existing between the parties prior to or simultaneously with this Agreement in connection with the
Purpose. For the sake of clarity, from and after the Effective Date, the NDA will remain in effect, other than as it applies to the Purpose, such that (i) any Confidential Information disclosed by one party to the other from and after the
Effective Date in connection with the Purpose will be subject to the confidentiality provisions of this Agreement, and (ii) any Confidential Information disclosed by one party to the other that is not in connection with the Purpose will remain
subject to the NDA. 

  

	 	8.5.	Export Regulation. Each party agrees to comply with all applicable export control laws and regulations, including the requirement for obtaining any export
license or agreement, if applicable. Without limiting the foregoing, each party agrees that it will not transfer any export controlled item, information, data, or technology, generated or received in connection with the Purpose, to foreign persons
employed by, associated with, or under contract to, such party in violation of applicable regulations. 

  

	 	8.6.	Force Majeure. If either party is prevented from or delayed in carrying out any of the provisions of this Agreement by reason of any acts of God, war, labor
disturbances, lack or failure of transportation facilities, sources of supply of labor, raw materials, power or supplies, or by reason of any law, order, proclamation, regulation, ordinance, demand or requirement of any Government or any
subdivision, authority or representatives of any such Government, or by reason of any other cause whatsoever beyond the reasonable control of such party, preventing or delaying the performance of its obligations hereunder, the party so prevented in
or delayed shall be excused from such performance to the extent and during the period of such prevention or delay, without, however, extending the term of this Agreement. 

  
 6 

* Confidential treatment requested 

	 	8.7.	Further agreement. Except as expressly set forth hereunder, nothing herein shall be deemed to provide a commitment by either party to enter into any further
agreement with the other party. 

  

	 	8.8.	Independence of the parties. Nothing in this Agreement shall grant to either party the right to make commitments of any kind for, or on behalf of, the other
party. This Agreement is not intended to be, nor shall it be construed as, a joint venture, teaming relationship, partnership, or other formal business arrangement. 

 

	 	8.9.	No assignability. Either party shall not, without prior written consent of the other party, assign this Agreement or any right or obligation hereunder, in whole
or in part, without prior written consent of the other party, except that the parties shall be entitled to assign this Agreement and/or such rights and obligations, to any of their respective Affiliates, and/or to any third party acquiring all or
substantially all assets of the business to which this Agreement relates, provided that such Affiliate and/or third party agree in writing to be bound by the terms of this Agreement. 

 

	 	8.10.	Notice. Any notice provided for in this Agreement, shall be in the English language and shall be served by registered mail, postage prepaid and shall be
therefore effective from the fifth day after the date of mailing. 

 Notices to Solvay shall be addressed to :

 SOLVAY SA 
 [***] 
 With a copy to : 

SOLVAY SA 
 [***] 
 Notices to Bioamber shall be addressed to : 

Attention: Jean-François Huc 

[***] 
 With a copy to : 
 Boivin Desbiens Senécal, s.e.n.c.

 [***] 
  

	 	8.11.	No variation. No variation of this Agreement shall be effective unless it is in writing signed by a duly authorized representative of each party.

  

	 	8.12.	Severability. In case any one of the provisions contained in this Agreement should be invalid, illegal or unenforceable in any respect in any jurisdiction, the
validity, legality and enforceability of such provision or provisions shall not in any way be affected or impaired thereby in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein and
therein shall not in any way be otherwise affected or impaired thereby. 

  

	 	8.13.	Waiver. No waiver by either party of any provision of this Agreement shall constitute a waiver of any other provision nor shall any waiver constitute a
continuing waiver. 

  
 7 

* Confidential treatment requested 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives in two (2) original copies, each party acknowledging having received its own copy. 
  

									
	SOLVAY SA	 		 	BIOAMBER INTERNATIONAL S.à.r.l.
			
	/s/ [***]	 		 	/s/ J.F. Huc
					
	    Name:	 	[***]	 		 	    Name:	 	 J.F. Huc

					
	    Title:	 	[***]	 		 	    Title:	 	 President

					
		 		 		 	    Name:	 	  

					
		 		 		 	    Title:	 	  

  
 8 

* Confidential treatment requested 

 Appendix: 
 Appendix A: General Outline Of Respective Tasks 
 [***] 

  
 9 

* Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]